Semiannual Report — FY2026 H1
What Takeda Pharmaceutical Company Limited reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-10-29View the original on EDINET
How much it says
37Thin
What moved here
23named for the first time
Its own wording
31terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
For the current interim consolidated accounting period (1 April 2026 to 30 September 2026), revenue was ¥2.407 trillion and R&D expenses were ¥338.6 billion, while both operating profit and interim profit increased from the previous interim period. The document also describes development and regulatory progress for key pipeline products, including a pediatric indication and an additional method of administration for ENTYVIO, and acceptance of the application for TAK-279 for psoriasis.
Komori's summary of this document, not the document's own words.37Thin
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
45
Typical
0
Almost nothing
62
Detailed
0
Almost nothing
41
Thin
27
Almost nothing
31
Thin
0
Almost nothing
79
Very detailed
50
Typical
R&D spend3,386億円Money spent making new things.
Cash left over3,231億円Cash from the business, less what went into equipment.
Spent on equipment985億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.